TRIL · Trillium Therapeutics
Acquired Company
Pfizer completed its acquisition of Trillium Therapeutics for $18.50 per share in cash, with a total purchase price of approximately $2.22 billion.
Under normal circumstances, the fund will invest at least 80% of the fund’s net assets (plus borrowings for investment purposes) in Trillion Dollar Assets and/or financial instruments (such as options or swaps) that provide indirect exposure to Trillion Dollar Assets.
Market Cap
N/A
52 Wk Range
$23.52 - $26.03
Previous Close
$24.33
Open
$23.52
Volume
8
Day Range
$23.52 - $23.52
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
N/A
Institutional Own.
N/A
Qtr Updated
N/A